In comments submitted Saturday, AHA generally supports the Centers for Medicare & Medicaid Services’ initial guidance implementing inflation rebates for certain single source drugs and biosimilar biological products covered by Medicare Part B, but recommends changes to prevent incentivizing drug shortages and burdening 340B hospitals. Drug units purchased under the 340B program are not subject to the Inflation Reduction Act rebates.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services June 8 announced plans to test a new Medicare and Medicaid primary care model in eight states beginning…
Headline
The Centers for Medicare & Medicaid Services June 7 finalized a policy governing the treatment of Medicare Part C days when calculating a…
Headline
Over 30 organizations, including the AHA, urged Congress to swiftly pass the Saving Access to Laboratory Services Act (S. 1000/H.R. 2377), bipartisan…
Headline
As the House Energy and Commerce Committee prepares to consider a legislative provision (H.R. 3561) that would reduce payments for drug administration services…
Headline
AHA May 17 shared with the Homeland Security and Governmental Affairs Permanent Subcommittee on Investigations its concern that some MA plans inappropriately…
Headline
The Centers for Medicare and Medicare Services announced plans to start an AHA-opposed demonstration for inpatient rehabilitation facilities Aug. 21…